Newsroom

Featured News

Date	Title and Summary
Toggle Summary Jun 3, 2018	CTV News - Safely Skipping Chemotherapy
Toggle Summary Mar 30, 2018	Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized
Toggle Summary Feb 26, 2018	Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistant Prostate Cancer
Toggle Summary Sep 7, 2018	German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 REDWOOD CITY, Calif. , Sept. 7, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced the

Latest Press Releases

Date	Title and Summary
Toggle Summary Sep 13, 2017	Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla™ Platform
Toggle Summary Dec 3, 2018	Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test REDWOOD CITY, Calif. and MECHELEN, Belgium , Dec. 3, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have
Toggle Summary Nov 28, 2017	Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests Global Licensing Agreement Provides Genomic Health with Exclusive Rights to Cleveland Diagnostics' Proprietary IsoPSA™ Technology
Toggle Summary Mar 8, 2018	Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full-year Profit on a Non-GAAP Basis Excluding Business Development Transaction Costs Delivered 7 Percent Test Growth and 6 Percent Revenue Growth in the Fourth Quarter Guides to Double-digit Revenue Growth and Full-year Profitability in 2018